slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 75,631-75,660
Pages 3,679
Rows per page 30
Component
75,631-75,660 of 110,355
13
The slide uses a process flow diagram to show the progression of the trial parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
The slide outlines two distinct study designs (COMP 005 and COMP 006) with specific primary endpoints at week 6.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The chart illustrates the pharmacokinetic advantage of IV delivery over oral administration.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide uses a line chart to show longitudinal changes in HCQ-29 subscales across three time points (Pre-dose, Discharge, 1 Month).ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
The slide demonstrates an inverted U-shaped dose response curve.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
Slide 32 of the deck.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
10
The slide uses a hub-and-spoke diagram to link the company to five specific capital allocation projects.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
20
The table presents normalized operating loss and EPS, excluding specific exceptional items as detailed in the footnotes.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
21
The table reconciles reported operating loss to normalised operating loss by adding back non-recurring restructuring and transaction-related costs.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to illustrate the binding mechanism.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a visual comparison framework to illustrate the mechanism of action (MOA) of the drug candidate.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
13
Data cut date: 15Nov23BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Data cut date: 15Nov23. Pt = Platinum.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
Data table showing safety profile by dose cohort.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The slide highlights a low incidence of immune-related adverse events (2 out of 18 patients).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
24
The slide uses a 2x2 grid of metrics to frame the problem/opportunity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
25
Includes comparative context to historical studies (pazopanib, pembrolizumab).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
26
Includes decision criteria for 'Go'/'No Go' based on clinical response and PFS rates.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
27
Includes specific adverse event data and clinical observations.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
29
The slide uses a grid of metrics to define the addressable market and the clinical problem (progression after 1L).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
31
The slide outlines a clinical trial protocol including patient disposition criteria and study endpoints.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
32
The table highlights the heavy pretreatment status of the patient population, specifically noting that a significant portion received 3 or more prior systemic therapies.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
33
Includes specific response rates, disease control rates, and confidence intervals for two patient cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
34
Waterfall plot shows best percentage change from baseline; spider plot shows change over time in weeks.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
36
Includes PET scan imagery comparing baseline to post-treatment status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
37
Data presented at IASLC 2023 North America Conference on Lung Cancer.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
39
Mentions FDA Project Optimus, which is a regulatory initiative for dose optimization in oncology trials.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit